Expert Perspectives on the Evolving Treatment Landscape of Multiple Myeloma : Episode 1

Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma

Dec 22, 2022

Sagar Lonial, MD
Amrita Krishnan, MD

Sagar Lonial, MD, introduces the expert panel and starts a conversation on data updates in the treatment of transplant-eligible multiple myeloma.

EP: 1.Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma

EP: 2.Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma

Related Videos

Related Content

Patient Assessment Drives Treatment Advances in Multiple Myeloma

February 6th 2023

Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment

December 22nd 2022

Updated MAIA Data Show D-Rd Maintains Survival Benefit Over Rd in Transplant-Ineligible, Newly Diagnosed Myeloma

January 29th 2023

Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care

October 27th 2022

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25th 2023

Ide-cel Elicits Durable Responses in High-risk Myeloma After Inadequate ASCT Response

January 24th 2023

Patient Assessment Drives Treatment Advances in Multiple Myeloma

February 6th 2023

Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment

December 22nd 2022

Updated MAIA Data Show D-Rd Maintains Survival Benefit Over Rd in Transplant-Ineligible, Newly Diagnosed Myeloma

January 29th 2023

Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care

October 27th 2022

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25th 2023

Ide-cel Elicits Durable Responses in High-risk Myeloma After Inadequate ASCT Response

January 24th 2023

Patient Assessment Drives Treatment Advances in Multiple Myeloma

February 6th 2023

Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment

December 22nd 2022

Updated MAIA Data Show D-Rd Maintains Survival Benefit Over Rd in Transplant-Ineligible, Newly Diagnosed Myeloma

January 29th 2023

Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care

October 27th 2022

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25th 2023

Ide-cel Elicits Durable Responses in High-risk Myeloma After Inadequate ASCT Response

January 24th 2023

Related Content

Patient Assessment Drives Treatment Advances in Multiple Myeloma

February 6th 2023

Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment

December 22nd 2022

Updated MAIA Data Show D-Rd Maintains Survival Benefit Over Rd in Transplant-Ineligible, Newly Diagnosed Myeloma

January 29th 2023

Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care

October 27th 2022

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25th 2023

Ide-cel Elicits Durable Responses in High-risk Myeloma After Inadequate ASCT Response

January 24th 2023

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.